DigestRedComo funciona
Red
/
Empresas
Ka
No verificado

KalVista Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

74 Comunicados de prensa

Ver todos los comunicados de prensa
10/11/2025
Web y redes sociales
Telefonía
Mercado de valores
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/11/2025
Eventos
Industria
Salud
Biotecnología
Sanidad
Medicina - Varios
Farmacéutica
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
05/11/2025
Salud
Ciencia
Farmacéutica
Biotecnología
Eventos
Web y redes sociales
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
03/11/2025
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
30/10/2025
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/10/2025
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/10/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
02/10/2025
Biotecnología
Salud
Ciencia
Farmacéutica
Mercado laboral
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
26/09/2025
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
25/09/2025
Acciones y Obligaciones
Biotecnología
Salud
Ciencia
Farmacéutica
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031
Fuente
KalVista Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0